top of page

Our Mission

To End Cancer Worldwide. 

Calviri is dedicated to making transformative improvements to healthspans and lifespans, globally, for people and their pets. 

Our Milestones & Accomplishments

Published pre-clinical studies validating vaccine platform

Created proprietary database of all human and pet mRNA-derived neoantigens (REDNs)

Validated diagnostic sensitivity and specificity for stage 1 tumor detection on our Diagnostic chips

Completed 800+ dog 5 year trial showing safety and efficacy of our vaccine

Collected largest bank of blood from pets with

stage 1 tumors

Developed a process for functionally screening for immunogenic, shared neoantigens on our Discovery chips

Established scalable manufacturing of Diagnostic chips

Business Plan & Product Timeline

Calviri will produce the dog diagnostics and vaccines, then use the data and revenues to transition to production of human versions. Diagnostics will be licensed to strategics for commercialization, the vaccines will be retained and commercialized internally by Calviri. 

Business Plan and Timeline

Our Cancer Products

​Early Diagnostics:

Early Detection: We have invented universal, peptide diagnostic chips that solve the sensitivity problem for detecting most stage 1 cancers, using a single test. It accurately measures tumor-specific antibody responses in a small amount of blood. 

 

Therapeutic Vaccines:

Vaccines to Treat: We have discovered a unique, rich source of immunogenic, shared tumor neoantigens that provides components for off-the-shelf therapeutic vaccines. These will serve as companion products to our early diagnostic tests.  

 

Preventative Vaccines 

Vaccines to Prevent: The same rich source of immunogenic neoantigens that are shared among tumors, even very different tumor types, provides components for off-the-shelf preventative vaccines. Instead of treating early cancer, these vaccines will prevent early cancer. 

Our Cancer Products

Literature & Media

Presentations, Webinars & Events

Calviri’s insights and innovations allow us to make diagnostics and vaccines that have already shown the potential to enormously impact health, globally. These products are all based on our unique neoantigens and chips; they are the key. Our canine preventative cancer vaccine is working. The data demonstrating our diagnostic capabilities will drive partnership and licensing negotiations for the dog diagnostic tests. Calviri’s neoantigens and chips make ending cancer possible.

Let End Cancer Investor Deck

Latest LIVE

Webinar

Previous Presentations & Events

2024

BIO International (June)

AACR Partnering (April)

Venture Café Phoenix (April)

Phoestival of Health-PBC (April)

Cancer at the Crossroads (March)

2023

MedInvest Oncology Investor Conference

World Vaccine Congress West Coast

Genetic Predisposition to Primary CNS Cancer

Venture Care

Senate Health Committee-State Capital

USDA

2022

World Vaccine & Immonotherapy Summit

Vaccine Summit Washington, DC

Next Generation Cancer Vaccine Development Summit

NCI Animal Model Workshop

2020

World Vaccine Congress

JP Morgan

Preventive Cancer Vaccine 

 

Event

​

Spotlight on Cancer Early Detection 

 

Cancer Prevention​​

​

Event


Calviri aims to end cancer worldwide with a diagnostic to detect cancer early and vaccines to treat or even pervent cancer

 

Demonstration of a Universal Preventative Cancer Vaccine

​

A Vaccine Strategy to Prevent Cancer

​

Preventing Cancer Might Be Easier Than Most Think

​

Our work to end cancer and connection to ASU

 

Vaccine Data for USDA

 

A new approach to therapeutic cancer vaccines; A novel platform for early diagnosis & predicting responses to immune checkpoint inhibitor treatment

 

A New Source of Cancer NeoAntigens as the Basis for a Broadly Preventative Cancer Vaccine

​

The case for creating a broadly protective preventative cancer vaccine: Report on a large canine clinical Trial Testing the concept; A simple blood-based assay to predict response to immunotherapy and immune related adverse events

​

Animal Models for Cancer

RNA Frameshift Errors Provide New Vaccine Product Opportunities Against Cancer

 

Ending Death from Cancer - Calviri presents investment opportunity

2019

Arizona Bioindustry Association

Midwestern University

Molecular Med Tri-Con

Molecular Med Tri-Con

PepTalk

Going to the Dogs – How the Largest Canine Clinical Trial in History May Lead to New Hope for Humans

 

Shifting the paradigm in diagnosing and treating cancer

 

RNA generated frameshift neoantigens in tumors are useful in diagnosis and vaccination

 

Using a blood-based 400K frameshift peptide array to develop cancer type-specific vaccinations

 

A new source of neoantigens and a platform for their discovery

2018

Molecular Med Tri-Con

Immune Oncology Summit

American College of Veterinary Internal Medicine

Golden Retriever Club of America

United States Patent and Trademark Office

European NeoAG Summit

Cancer type specific FAST vaccines based on frameshift neoantigens

 

Tapping a new source of neoantigens: applications in therapy and diagnostics

 

A new blood based approach to early diagnosis of cancer

 

Calviri’s Technology Enables a Universal Preventative Vaccine

 

Inventions to effectively eradicate cancer

 

Shifting the paradigm in diagnosing and treating cancer

2018

Golden Retriever Club of America

An alternative source of neoantigens offers new approaches to personal and general vaccines

Contact Us

Please direct any questions or comments you have for us via our contact form below.

Wexford-50-phoenix-Project-Hero-Image-PBC-1.jpg

850 N. 5th Street Phoenix, AZ

Thanks for submitting!

bottom of page